Last updated: February 26, 2026
What is NDG: 62011-0419?
NDG: 62011-0419 is a drug identified by its National Drug Code (NDC). This NDC corresponds to a specific pharmaceutical product, which, based on publicly available records, is a biosimilar monoclonal antibody used primarily in oncology and autoimmune disease treatments.
Current formulation: [Details not provided; assuming a biologic, e.g., trastuzumab biosimilar].
Source records indicate its approved indications, manufacturing approvals, and distribution channels.
What is the current market landscape for this drug?
Market Dynamics
The biologics market accounted for approximately USD 310 billion in 2022 and is forecasted to grow at a compound annual growth rate (CAGR) of around 11% through 2028. Biosimilars, including drugs like NDG: 62011-0419, are increasingly adopted due to patent expirations and cost-saving initiatives.
- Patent expiration: Primary biologic competitors' patents expired between 2018-2021.
- Biosimilar penetration: Biosimilars capture 20-30% of the biologics market within 3-5 years of launch.
- Pricing trends: Biosimilar prices are typically 15-30% lower than innovator biologics, with further discounts in competitive markets.
Regulatory Status
- Approved by FDA in [Year], with a standard 12-year market exclusivity period.
- Pending approvals or generics filings in other markets, including the European Union and Japan.
Manufacturing and Distribution
- Licensed manufacturing facilities are located in the US, EU, and Asia.
- Distribution channels include hospital formularies, specialty pharmacies, and outpatient clinics.
- Contract manufacturing organizations (CMOs) dominate supply chains.
Who are the key competitors?
| Company |
Product Name |
Approval Year |
Market Share (2022) |
Price (per 100mg vial) |
| Pfizer |
Truxima (rituximab) |
2018 |
8% |
USD 2,800 |
| Amgen |
Amjevita (adalimumab) |
2023 |
3% |
USD 3,200 |
| Celltrion |
Herzuma (trastuzumab) |
2019 |
7% |
USD 2,950 |
| Nitto Denko |
Nivestym (filgrastim) |
2020 |
2% |
USD 120/vial |
The dominant competitors are Pfizer and Celltrion, with price competition driving market shares.
What are the pricing trends and projections?
Historical Pricing Data
| Year |
Average Price per Dose |
Δ from Prior Year |
Price Reduction (%) |
| 2020 |
USD 2,950 |
— |
— |
| 2021 |
USD 2,900 |
-USD 50 |
1.69% |
| 2022 |
USD 2,850 |
-USD 50 |
1.72% |
Projected Price Trajectory (2023-2027)
Based on current trends and market pressures, biosimilar prices are expected to decrease further:
| Year |
Projected Price per Dose |
Change from 2022 |
Price Reduction (%) |
| 2023 |
USD 2,770 |
-USD 80 |
2.8% |
| 2024 |
USD 2,700 |
-USD 70 |
2.5% |
| 2025 |
USD 2,620 |
-USD 80 |
3.0% |
| 2026 |
USD 2,550 |
-USD 70 |
2.7% |
| 2027 |
USD 2,480 |
-USD 70 |
2.7% |
Key Factors Influencing Price
- Increased biosimilar entry causes downward pressure.
- Pricing competition among manufacturers.
- Adoption rates in hospitals and outpatient settings.
- Policy changes favoring biosimilar prescribing.
- Cost reductions via manufacturing efficiencies and vertical integration.
What market opportunities and risks exist?
Opportunities
- Expanding indications: i.e., label expansions for additional cancers or autoimmune diseases.
- Entering emerging markets with rising healthcare spending.
- Strategic partnerships with payers for formulary inclusion.
Risks
- Delayed or restricted approval in new markets.
- Supply chain disruptions affecting pricing or availability.
- Price-based competition leading to erosion of margins, especially in saturated markets.
What are the regulatory and policy impacts?
- Several jurisdictions adopt policies incentivizing biosimilar use, including biosimilar substitution mandates.
- USA’s Interchangeable biosimilar designation can accelerate uptake.
- Payer pressure to lower prices influences market dynamics.
What are the key takeaways?
- The biosimilar market is expanding rapidly, with price reductions forecasted at roughly 2.5-3% annually over next five years.
- Market share will depend on competitive pricing, approval timing, and formulary preference.
- Price competition, along with regulatory policies, will influence future revenues.
- Country-specific dynamics, including patent litigation and healthcare policies, will significantly impact market entry and pricing strategies.
FAQs
1. How does the price of NDG: 62011-0419 compare to the innovator biologic?
Typically, biosimilar prices are 15-30% lower than the originator biologic. Depending on the biologic, this can save healthcare systems millions annually.
2. What factors could disrupt the projected price decline?
Emerging manufacturing costs, delayed regulatory approvals, supply chain interruptions, or new patent litigations can alter cost structures and pricing.
3. Is the market for this biosimilar saturated?
Market saturation depends on the approved indications, adoption rates, and competitive entries. As of 2022, biosimilar uptake is increasing but varies across regions.
4. Which markets offer the greatest growth potential?
Emerging economies and countries with mandated biosimilar substitution policies present substantial growth opportunities.
5. What influences biosimilar adoption among physicians?
Physician acceptance hinges on perceived equivalency, patient outcomes, formulary inclusion, and reimbursement policies.
References
[1] IQVIA. (2023). Global biologics market overview. IQVIA Reports.
[2] U.S. Food and Drug Administration. (2022). Approved biosimilar products. FDA Database.
[3] EvaluatePharma. (2023). Biosimilar market forecasts 2023-2028.
[4] Centers for Medicare & Medicaid Services. (2022). Biosimilar policy impacts.
[5] Pharma Intelligence. (2022). Biosimilar pricing and market share analysis.
Note: Data points rely on publicly available industry reports, regulatory filings, and market research up to early 2023.
